Search This Blog

Sunday, August 6, 2023

2023 shaping up to be biggest year for biopharma M&A since pandemic

2023 is shaping up to be the biggest year for biopharma M&A since the pandemic, despite increased FTC scrutiny and rising capital costs.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)